摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridine | 913377-46-5

中文名称
——
中文别名
——
英文名称
7-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridine
英文别名
5-(7-chlorothieno[3,2-b]pyridin-2-yl)-3-methyl-1,2,4-oxadiazole
7-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridine化学式
CAS
913377-46-5
化学式
C10H6ClN3OS
mdl
——
分子量
251.696
InChiKey
AAYSAVHDLWDSDN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    423.9±55.0 °C(Predicted)
  • 密度:
    1.489±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    80
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Aurora Kinase Modulators and Method of Use
    申请人:Amgen Inc.
    公开号:US20140336182A1
    公开(公告)日:2014-11-13
    The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    本发明涉及具有一般式I的化合物,其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义,并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如,这些化合物能够调节枢纽激酶,从而影响细胞周期和细胞增殖过程,以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物,以及治疗与枢纽激酶活性相关的疾病状态的方法。
  • Aurora kinase modulators and method of use
    申请人:Cee Victor
    公开号:US20090069297A1
    公开(公告)日:2009-03-12
    The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    本发明涉及具有一般式I的化合物,其中A1-8,D',L1,L2,R1,R6-8和n在此定义,并且合成中间体,它们能够调节各种蛋白激酶受体酶,并因此影响与这些激酶活动相关的各种疾病状态和情况。例如,这些化合物能够调节极化激酶,从而影响细胞周期和细胞增殖过程,以治疗癌症和与癌症相关的疾病。本发明还包括包括这些化合物的药物组合物以及治疗与极化激酶活性相关的疾病状态的方法。
  • Substituted amide derivatives and methods of use
    申请人:Kim Tae-Seong
    公开号:US20080312232A1
    公开(公告)日:2008-12-18
    Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    所选化合物对于预防和治疗疾病,如HGF介导的疾病具有有效性。本发明涵盖了新型化合物、类似物、前药及其药学上可接受的盐、药物组合物和用于预防和治疗涉及癌症等疾病和其他疾病或状况的方法。本发明还涉及制备这些化合物的过程,以及在这些过程中有用的中间体。
  • AURORA KINASE MODULATORS AND METHOD OF USE
    申请人:Deak Holly
    公开号:US20100280008A1
    公开(公告)日:2010-11-04
    The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    本发明涉及具有一般式I的化合物,其中A1-8、D'、L1、L2、R1、R6-8和n在此定义,并且合成中间体能够调节各种蛋白激酶受体酶,从而影响与这些激酶活动相关的各种疾病状态和条件。例如,这些化合物能够调节极化分裂激酶,从而影响细胞周期和细胞增殖的过程,以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物以及治疗与极化分裂激酶活性相关的疾病状态的方法。
  • METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES
    申请人:KIM Tae-Seong
    公开号:US20120070413A1
    公开(公告)日:2012-03-22
    Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    选定的化合物对于预防和治疗疾病,如HGF介导的疾病非常有效。本发明包括新颖的化合物、类似物、前药和其药学上可接受的盐、制药组合物以及用于预防和治疗涉及癌症等疾病和其他疾病或情况的方法。本发明还涉及制备这些化合物的过程以及在这些过程中有用的中间体。
查看更多

同类化合物

钠3-氨基-4,6-二甲基噻吩并[2,3-b]吡啶-2-羧酸酯 脱乙酰基2-O-叔-丁基二甲基硅烷基普拉格雷 羟基(噻吩并[2,3-b]吡啶-3-基)乙腈 盐酸噻氯匹定 甲基4-溴7-氧-6,7-二氢噻吩并[2,3-C]吡啶-2-羧酸酯 甲基3-甲基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基-4-(二甲基氨基)噻吩并[2,3-b]吡啶-2-羧酸酯 甲基3-氨基-4,5,6-三甲基噻吩并[2,3-b]吡啶-2-羧酸酯 甲基2,4-二甲基噻吩并[3,4-b]吡啶-7-羧酸酯 替诺立定 普拉格雷羟基硫内酯 普拉格雷盐酸盐 普拉格雷杂质III 普拉格雷杂质1 普拉格雷杂质 普拉格雷 外消旋-2-(2-氯苯基)-(6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基)乙腈 噻氯吡啶杂质F 噻氯吡啶杂质E 噻氯匹定杂质8 噻氯匹定N-氧化物 噻氯匹定3-氯异构体 噻氯匹定 噻氯匹丁-d4 噻吩并吡啶酮 噻吩并吡啶-2-甲酸甲酯 噻吩并[3,4-b]吡啶-5,7-二酮 噻吩并[3,2:3,4]环戊二烯并[1,2-b]吖丙因(9CI) 噻吩并[3,2-c]吡啶-3-胺 噻吩并[3,2-c]吡啶-3-羧醛 噻吩并[3,2-c]吡啶-2-羧酸甲酯 噻吩并[3,2-c]吡啶-2-羧酸 噻吩并[3,2-c]吡啶-2-基硼酸 噻吩并[3,2-c]吡啶 噻吩并[3,2-b]吡啶-7-羧酸 噻吩并[3,2-b]吡啶-6-醇 噻吩并[3,2-b]吡啶-6-胺 噻吩并[3,2-b]吡啶-6-羧酸甲酯 噻吩并[3,2-b]吡啶-6-羧酸 噻吩并[3,2-b]吡啶-5-羧酸 噻吩并[3,2-b]吡啶-3-胺 噻吩并[3,2-b]吡啶-2-羧酸甲酯 噻吩并[3,2-b]吡啶-2-羧酸 噻吩并[3,2-b]吡啶-2-甲醇 噻吩并[3,2-C]吡啶-2-硼酸频那醇酯 噻吩并[3,2-B]吡啶-3-羧酸甲酯 噻吩并[2,3-c]吡啶-7-胺 噻吩并[2,3-c]吡啶-7-羧酸甲酯 噻吩并[2,3-c]吡啶-7-羧酸